id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1999-N-0114-0009,FDA,FDA-1999-N-0114,"Hepatitis C Virus ‘‘Lookback’’ Requirements Based on Review of
Historical Testing Records; Technical Amendment",Rule,Final Rule,2015-12-28T05:00:00Z,2015,12,2015-12-28T05:00:00Z,,2024-10-03T21:48:52Z,2015-32477,0,0,0900006481dd4203
FDA-1999-N-0114-0008,FDA,FDA-1999-N-0114,Supporting Statement re OMB Information Collection Supporting Statement,Supporting & Related Material,Statement (Supporting and Related Material),2007-10-25T04:00:00Z,2007,10,,,2024-10-03T22:26:59Z,,0,0,09000064804ae8ea
FDA-1999-N-0114-0007,FDA,FDA-1999-N-0114,"Notice of Approval re Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; CGMP for Blood and Blood Components; Notification of Consignees and Transfusion Recipients Receiving Blood and Blood Components at Increased Risk of Transmitting HCV Infection (""Lookback"")",Notice,Notice of Approval,2007-10-25T04:00:00Z,2007,10,2007-10-25T04:00:00Z,,2024-10-03T21:46:36Z,72FR48766,0,0,09000064804ae8e8
FDA-1999-N-0114-0005,FDA,FDA-1999-N-0114,Reference from FDA/CBER re OMB Changes,Supporting & Related Material,Reference (internal unless indicated),2007-08-28T04:00:00Z,2007,8,,,2024-10-03T22:21:48Z,,0,0,09000064804ae8e6
FDA-1999-N-0114-0006,FDA,FDA-1999-N-0114,Reference from FDA/CBER re OMB Changes,Supporting & Related Material,Reference (internal unless indicated),2007-08-28T04:00:00Z,2007,8,,,2024-10-03T22:23:43Z,,0,0,09000064804ae8e7
FDA-1999-N-0114-0001,FDA,FDA-1999-N-0114,"Notice of Final Rule re Current Good Manufacturing Practice for Blood and Blood Components; Notification of Consignees and Transfusion Recipients Receiving Blood and Blood Components at Increased Risk of Transmitting Hepatitis C Virus Infection (""Lookback"")",Notice,Notice of Final Rule,2007-08-27T04:00:00Z,2007,8,2007-08-24T04:00:00Z,,2024-10-03T21:47:06Z,66FR31146 - 31159,0,0,09000064804ae8d2
FDA-1999-N-0114-0004,FDA,FDA-1999-N-0114,"Notice of Final Rule re Current Good Manufacturing Practice for Blood and Blood Components; Notification of Consignees and Transfusion Recipients Receiving Blood and Blood Components at Increased Risk of Transmitting Hepatitis C Virus Infection (""Lookback"")",Notice,Notice of Final Rule,2007-08-27T04:00:00Z,2007,8,2007-08-24T04:00:00Z,,2024-10-03T21:46:57Z,66FR31146 - 31159,0,0,09000064804ae8e5
FDA-1999-N-0114-0002,FDA,FDA-1999-N-0114,FDA/CBER Reference re HCV Lookback; Proposed Rule,Supporting & Related Material,Reference (internal unless indicated),2002-10-10T04:00:00Z,2002,10,,,2024-10-03T22:16:05Z,,0,0,09000064804ae8e2
FDA-1999-N-0114-0003,FDA,FDA-1999-N-0114,FDA/CBER Reference re HCV Lookback; Proposed Rule,Supporting & Related Material,Reference (internal unless indicated),2002-10-10T04:00:00Z,2002,10,,,2024-10-03T22:19:14Z,,0,0,09000064804ae8e3